Outcome measures in interventional trials for prevention or treatment of venous thrombosis in the pediatric population

Seminars in Thrombosis and Hemostasis

Volumn 37, Issue 7, 2011, Pages 840-847

  Mitchell, Lesley G ^a   Male, Christoph ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

deep vein thrombosis; interventional trials; Outcome measures; pediatrics

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN III CONCENTRATE; HIRULOG; REVIPARIN; TINZAPARIN; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; CHILDHOOD DISEASE; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DIAGNOSTIC VALUE; DISEASE COURSE; DRUG COST; DRUG EFFICACY; HEALTH CARE POLICY; HEALTH CARE QUALITY; HUMAN; INTERVENTION STUDY; OUTCOME ASSESSMENT; PATIENT CARE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHLEBOGRAPHY; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROPHYLAXIS; QUALITY OF LIFE; THROMBIN TIME; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOEMBOLISM; TREATMENT OUTCOME; TREATMENT PLANNING; ULTRASOUND;

ADOLESCENT; CATHETERIZATION, CENTRAL VENOUS; CHILD; CLINICAL TRIALS AS TOPIC; HEMORRHAGE; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PHLEBOGRAPHY; POSTTHROMBOTIC SYNDROME; QUALITY OF LIFE; RESEARCH DESIGN; VENOUS THROMBOSIS;

EID: 84055222111     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0031-1297176     Document Type: Article

References (31)

1. Massicotte P, Julian J A., Gent M et al, PROTEKT Study Group. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thromb Res 2003 109 2-3 101-108 (Pubitemid 36428760)
2. Massicotte P, Julian J A., Gent M et al, REVIVE Study Group. An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thromb Res 2003 109 2-3 85-92 (Pubitemid 36428758)
3. Mitchell L, Andrew M, Hanna K et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thromb Haemost 2003 90 2 235-244 (Pubitemid 36992499)
4. Alton G Y., Robertson C M., Sauve R et al, Western Canadian Complex Pediatric Therapies Project Follow-Up Group. Early childhood health, growth, and neurodevelopmental outcomes after complete repair of total anomalous pulmonary venous connection at 6 weeks or younger. J Thorac Cardiovasc Surg 2007 133 4 905-911
5. Kuhle S, Massicotte P, Dinyari M et al. Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic events. Thromb Haemost 2005 94 6 1164-1171 (Pubitemid 41819610)
6. Ruud E, Holmstrm H, De Lange C, Hogstad E M., Wesenberg F. Low-dose warfarin for the prevention of central line-associated thromboses in children with malignanciesa randomized, controlled study. Acta Paediatr 2006 95 9 1053-1059 (Pubitemid 44385108)
7. Schroeder A R., Axelrod D M., Silverman N H., Rubesova E, Merkel E, Roth S J. A continuous heparin infusion does not prevent catheter-related thrombosis in infants after cardiac surgery. Pediatr Crit Care Med 2010 11 4 489-495
8. Young G, Tarantino M D., Wohrley J, Weber L C., Belvedere M, Nugent D J. Pilot dose-finding and safety study of bivalirudin in infants <6 months of age with thrombosis. J Thromb Haemost 2007 5 8 1654-1659 (Pubitemid 47091407)
9. Mitchell L G., Goldenberg N A., Male C, Kenet G, Monagle P, Nowak-Göttl U, on behalf of the Perinatal and Paediatric Haemostasis Subcommittee of the SSC of the ISTH. Definition of clinical efficacy and safety outcomes for clinical trials in deep venous thrombosis and pulmonary embolism in children. J Thromb Haemost 2011 9 9 1856-1858
10. Lensing A W., Hirsh J, Buller H R. Diagnosing venous thrombosis. In: Hirch J, Schulman S, eds Venous Thrombosis. Philadelphia J.B. Lippincott 1994 1297-1321
11. Molloy W, English J, O'Dwyer R, O'Connell J. Clinical findings in the diagnosis of proximal deep vein thrombosis. Ir Med J 1982 75 4 119-120 (Pubitemid 12130004)
12. Mitchell L G., Andrew M, Hanna K et al, Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase Group (PARKAA). A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study. Cancer 2003 97 2 508-516 (Pubitemid 36133819)
13. Lensing A W., Bller H R., Prandoni P et al. Contrast venography, the gold standard for the diagnosis of deep-vein thrombosis: improvement in observer agreement. Thromb Haemost 1992 67 1 8-12
14. Prandoni P, Polistena P, Bernardi E et al. Upper-extremity deep vein thrombosis. Risk factors, diagnosis, and complications. Arch Intern Med 1997 157 1 57-62 (Pubitemid 27027075)
15. Lensing A W., Prandoni P, Brandjes D et al. Detection of deep-vein thrombosis by real-time B-mode ultrasonography. N Engl J Med 1989 320 6 342-345 (Pubitemid 19106869)
16. Baarslag H J., van Beek E J., Koopman M M., Reekers J A. Prospective study of color duplex ultrasonography compared with contrast venography in patients suspected of having deep venous thrombosis of the upper extremities. Ann Intern Med 2002 136 12 865-872 (Pubitemid 34625698)
17. Male C, Chait P, Ginsberg J S. et al. Comparison of venography and ultrasound for the diagnosis of asymptomatic deep vein thrombosis in the upper body in children: results of the PARKAA study. Prophylactic Antithrombin Replacement in Kids with ALL treated with Asparaginase. Thromb Haemost 2002 87 4 593-598 (Pubitemid 34302946)
18. Baarslag H J., Koopman M M., Reekers J A., van Beek E J. Diagnosis and management of deep vein thrombosis of the upper extremity: a review. Eur Radiol 2004 14 7 1263-1274 (Pubitemid 38979221)
19. Kuhle S, Spavor M, Massicotte P et al. Prevalence of post-thrombotic syndrome following asymptomatic thrombosis in survivors of acute lymphoblastic leukemia. J Thromb Haemost 2008 6 4 589-594 (Pubitemid 351404925)
20. Kuhle S, Koloshuk B, Marzinotto V et al. A cross-sectional study evaluating post-thrombotic syndrome in children. Thromb Res 2003 111 4-5 227-233 (Pubitemid 38021940)
21. van Ommen C H., Ottenkamp J, Lam J et al. The risk of postthrombotic syndrome in children with congenital heart disease. J Pediatr 2002 141 4 582-586 (Pubitemid 35193328)
22. Goldenberg N A., Knapp-Clevenger R, Manco-Johnson M J., Mountain States Regional Thrombophilia Group. Elevated plasma factor VIII and D-dimer levels as predictors of poor outcomes of thrombosis in children. N Engl J Med 2004 351 11 1081-1088 (Pubitemid 39167512)
23. Goldenberg N A., Durham J D., Knapp-Clevenger R, Manco-Johnson M J. A thrombolytic regimen for high-risk deep venous thrombosis may substantially reduce the risk of postthrombotic syndrome in children. Blood 2007 110 1 45-53 (Pubitemid 47026817)
24. Kreuz W, Stoll M, Junker R et al. Familial elevated factor VIII in children with symptomatic venous thrombosis and post-thrombotic syndrome: results of a multicenter study. Arterioscler Thromb Vasc Biol 2006 26 8 1901-1906 (Pubitemid 44305348)
25. Schobess R, Dring C, Bidlingmaier C, Heinecke A, Merkel N, Nowak-Göttl U. Long-term safety and efficacy data on childhood venous thrombosis treated with a low molecular weight heparin: an open-label pilot study of once-daily versus twice-daily enoxaparin administration. Haematologica 2006 91 12 1701-1704 (Pubitemid 46032970)
26. Sharathkumar A A., Pipe S W. Post-thrombotic syndrome in children: a single center experience. J Pediatr Hematol Oncol 2008 30 4 261-266 (Pubitemid 351507579)
27. van Ommen C H., Heijboer H, van den Dool E J., Hutten B A., Peters M. Pediatric venous thromboembolic disease in one single center: congenital prothrombotic disorders and the clinical outcome. J Thromb Haemost 2003 1 12 2516-2522
28. Galanis T, Thomson L, Palladino M, Merli G J. New oral anticoagulants. J Thromb Thrombolysis 2011 31 3 310-320
29. Nowak-Göttl U, Dietrich K, Schaffranek D et al. In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes. Blood 2010 116 26 6101-6105
30. Streif W, Andrew M, Marzinotto V et al. Analysis of warfarin therapy in pediatric patients: A prospective cohort study of 319 patients. Blood 1999 94 9 3007-3014 (Pubitemid 29512704)
31. Anton N, Cox P N., Massicotte M P. et al. Heparin-bonded central venous catheters do not reduce thrombosis in infants with congenital heart disease: a blinded randomized, controlled trial. Pediatrics 2009 123 3 e453-e458